Oramed Pharmaceuticals Revamps Debt Structure with Scilex
Oramed Pharmaceuticals Announces Debt Restructuring
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP), a clinical-stage pharmaceutical company specializing in developing oral drug delivery systems, has publicly announced a strategic restructuring of its debt obligations with Scilex Holding Company (NASDAQ: SCLX), a leader in non-opioid pain management solutions.
Details of the Partnership
In collaboration with Murchinson and 3i LP, Oramed has entered into definitive agreements to purchase and sell new tranche B senior secured convertible notes. This initiative involves a substantial investment of $50 million, along with warrants granting the right to purchase 7,500,000 shares of Oramed's common stock.
Restructuring Highlights
The restructuring plan includes the conversion of $22.5 million of the existing principal balance from Scilex’s Senior Secured Promissory Note. This note, originally scheduled for repayment between September 2024 and March 2025, will be replaced by a new note of $25 million, subject to a 10% discount and carrying an interest rate of 5.5% per annum. Additionally, the note is convertible into Scilex common stock at a price of $1.09, with a two-year maturity from the date of issuance.
Enhanced Warrants
As part of this strategic union, Oramed will obtain warrants to purchase up to 3.75 million shares of Scilex stock, also set at an exercise price of $1.09. Plus, a portion of $12.5 million from the new financing will directly contribute to repaying the outstanding debt on the Senior Secured Promissory Note to Oramed.
Deferred Payments and Future Plans
In response to ongoing negotiations, Oramed has agreed to extend certain payment deadlines from Scilex. This compromise allows Scilex additional time until October 7, 2024, to satisfy the conditions of the Senior Secured Promissory Note. The anticipated closing of the new financing is projected around the same time, contingent on specific closing conditions being met.
Participation in Future Royalties
Furthermore, Oramed is poised to gain an 8% royalty on the net sales of Scilex’s products, including the topical lidocaine preparation, ZTlido. This arrangement is strategically aligned to bolster Oramed's financial portfolio, with a $2.5 million reduction on the outstanding principal balance due to their engagement in acquiring royalty rights.
CEO’s Perspective on the Restructuring
Nadav Kidron, CEO of Oramed, expressed optimism regarding this restructuring, stating, "We believe that this restructuring significantly enhances the potential value of our investment in Scilex. While slightly extending the payment schedule of a portion of our investment, it offers us substantial potential upside, including through warrants and conversion options. We are excited to contribute to the growth trajectory of ZTlido, which resonates with our goal to maximize shareholder value while supporting innovative healthcare solutions."
About Oramed Pharmaceuticals
Oramed Pharmaceuticals (NASDAQ: ORMP) has emerged as a pioneering force in oral delivery solutions for drugs typically administered via injection. The company’s innovative Protein Oral Delivery (POD™) technology is designed to enhance drug integrity and absorption effectively. With operational offices in the United States and Israel, Oramed remains focused on advancing its delivery technologies to cater to various medical needs.
Company Contact Information
For further inquiries, reach out to Oramed Pharmaceuticals at +1-844-9-ORAMED or email ir@oramed.com.
Frequently Asked Questions
What is the primary aim of Oramed Pharmaceuticals' debt restructuring?
The restructuring aims to enhance the investment value in Scilex, providing Oramed with substantial potential upside through new convertible notes and warrants.
What are the key financial details involved in the restructuring?
Oramed is restructuring $22.5 million in existing debt, while acquiring new notes worth $25 million, along with warrants for shares of Scilex stock.
How will this restructuring benefit Oramed's shareholders?
Shareholders stand to gain from potential upsides related to warrants and conversion options, as well as an 8% royalty on select products from Scilex.
What role does ZTlido play in Oramed's new agreement?
Oramed will receive a royalty from the sales of ZTlido, linking Oramed's financial growth to the performance of Scilex's pain management products.
How can investors learn more about Oramed Pharmaceuticals?
Investors can visit Oramed's official website or contact them directly via the provided email or phone number to get more information on their operations and updates.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Experience Groceryshop 2024 with Ja Rule as Headliner
- Sila Realty Trust Shines with Strong Analyst Rating and Growth
- iHeartMedia Partners with Whalar Group to Empower Creators
- Understanding Short Interest Trends with Parker Hannifin (PH)
- Celebrate the Holiday Spirit with James Avery's Collection
- GBI Biomanufacturing Partners with Allterum for Drug Development
- Infinex Partners with Wormhole for Enhanced DeFi Solutions
- Belden Inc. Achieves Historic Stock Surge with Positive Outlook
- Pita Pit Partners with Killer Brownie® to Enhance Offerings
- Cummins Inc Reaches All-Time High with Robust Q2 Performance
Recent Articles
- Hometap Secures $278 Million to Enhance Home Equity Solutions
- Zitahli Launches TREKMATE PRO: The Ultimate Travel Companion
- Valiant Energy Solutions Unites with CSB for Enhanced Energy Services
- Regeneron Focuses on Muscle Preservation in Obesity Treatments
- Preverity Teams Up with Graves Gilbert Clinic for Patient Safety
- Innovative Alliance Enhancing Behavioral Health Care Solutions
- Cloud Services Empower U.S. Firms for Future Growth and Innovation
- Hyperlink InfoSystem Emerges as Leading Software Developer
- Terran Orbital Corporation Investors Encouraged to Join Lawsuit
- Acetone Market Set to Reach $7.55 Billion by 2031 with 5.4% Growth
- Exploring the Future of Access Control as a Service Market
- Luckey Farmers and Mid-Wood Merger: A New Chapter Begins
- Understanding the Shift in Retirement Income Concerns
- Fresh Thyme Market Predicts Top Food Trends for 2025
- Oscium Expands Offerings with the Acquisition of MetaGeek
- International Call for Media Freedom: Support for Mech Dara
- Butterfly Equity's Acquisition of The Duckhorn Portfolio
- Analyst Downgrade Picks Up Momentum for Amazon Shares
- Nvidia's Upcoming AI Summit: A New Era for Investors
- Revolution Medicines Showcases Innovative Research at Major Symposium
- Chinese Stocks Surge: Insights into Alibaba, JD, NIO, and More
- Scilex Holding Company Secures $50 Million Financing for Debt Revamp
- Freddie Mac Launches Comprehensive Tender Offer for STACR Notes
- Sodexo Unveils Innovative Frictionless Stores Across Campuses
- Hudbay Secures Resolution in Prolonged Civil Litigation Matters
- Banijay Rights Expands Reach for Highway Thru Hell Content
- Biomea Fusion Showcases Breakthroughs in Diabetes Therapy
- Analysis of Medicare Plans' Rising Administrative Costs
- Stock Market Update: Declines in Major Indices Reflect Trends
- China's Stock Rally: Causes, Concerns, and Future Outlook
- Air Products' Stock Soars After Activist Investor Engagement
- Weibo Corporation's Stock Hits New High with Promising Metrics
- Experts Revise AZZ Earnings Forecast Before Imminent Release
- RXDco Launches Eco-Friendly Cocoon Jars for Cannabis
- Duke Energy Florida Braces for Hurricane Milton Impact
- Brookdale Senior Living Faces Downgrade Amid Economic Strain
- Molecular Partners: Driving Innovation in Cancer Therapy
- Stratos Solutions Chooses Unanet for ERP to Foster Growth
- Brookfield Property Partners Achieves Record Stock Performance
- Get Well's Commitment to Social Determinants of Health Recognized
- Calamos Global Total Return Reaches New Heights in Market
- Aditx Therapeutics Faces Challenges Amid Stock Decline
- Generac Holdings Sees Stock Rally, Hits 52-Week High of $169.69
- BreachLock's Innovative Analytics Power Fortune 500 Security
- Citi Upgrades Air Products Stock Amid Strategic Changes
- Claros Mortgage Trust's Stock Performance and Future Outlook
- Understanding GORV's Struggles: An In-Depth Analysis
- Germany's Finance Minister Promises Recovery and Growth Strategies
- Surge in US Money Market Funds amidst Global Uncertainty
- Meta's Innovative Tech Ventures: Driving Future Potential Amid Losses